公开(公告)号：US20180155385A1

公开(公告)日：2018-06-07

申请号：US15576948

申请日：2016-05-23

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Cyril B. DOUSSON ,  David DUKHAN ,  Christophe Claude PARSY

IPC: C07H19/11 ,  A61P35/00

Abstract: The present invention relates to novel nucleoside derivatives, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.

公开(公告)号：US20190233463A1

公开(公告)日：2019-08-01

申请号：US16311363

申请日：2017-06-20

Applicant: MERCK SHARP & DOHME CORP. ,  IDENIX PHARMACEUTICALS LLC

Inventor： Stephane BOGEN ,  David DUKHAN ,  Guillaume BRANDT ,  Claire Pierra ROUVIERE ,  Cyril B. DOUSSON ,  Francois-Rene ALEXANDRE

IPC: C07H19/213 ,  C07H19/11 ,  A61K31/7076 ,  A61K31/7072 ,  A61K45/06 ,  A61P31/14

CPC classification number: C07H19/213 ,  A61K31/7072 ,  A61K31/7076 ,  A61K45/06 ,  A61P31/14 ,  C07H19/11 ,  A61K2300/00

Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.

公开(公告)号：US20180258130A1

公开(公告)日：2018-09-13

申请号：US15981813

申请日：2018-05-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Benjamin Alexander MAYES ,  Adel M. MOUSSA ,  Alistair James STEWART ,  Gilles GOSSELIN ,  Christophe Claude PARSY ,  François-René ALEXANDRE ,  Jean-François GRIFFON ,  Dominique SURLERAUX ,  Cyril B. DOUSSON ,  Claire PIERRA ,  Houcine RAHALI

IPC: C07H19/20 ,  C07H19/10 ,  A61K31/403 ,  C07H19/16 ,  A61K38/55 ,  A61K38/21 ,  A61K31/7056 ,  A61K31/708 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/7072 ,  A61K31/4709 ,  A61K31/497

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

公开(公告)号：US20170044205A1

公开(公告)日：2017-02-16

申请号：US15304506

申请日：2015-04-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： David DUKHAN ,  Cyril B. DOUSSON ,  Gilles GOSSELIN ,  Jean-Laurent PAPARIN ,  Guillaume BRANDT ,  Rachid RAHALI ,  Aurelien SALANSON ,  François-René ALEXANDRE

IPC: C07H19/20 ,  A61K31/7068 ,  C07H19/10 ,  A61K31/7072 ,  A61K45/06 ,  A61K31/7076

CPC classification number: C07H19/20 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K45/06 ,  C07H19/10 ,  C07H19/11

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

Abstract translation: 本文提供了用于治疗黄病毒科感染（包括HCV感染）的化合物，组合物和方法。 在某些实施方案中，公开了核苷衍生物的化合物和组合物，其可以单独施用或与其它抗病毒剂组合施用。 在某些实施方案中，化合物是式I的3'-取代的甲基或炔基核苷：（I）; 或其药学上可接受的盐，溶剂化物，立体异构形式，互变异构形式或其多晶型形式，其中碱，PD，RA，RB1，RB2，RC和Z如本文所定义。

公开(公告)号：US20160002281A1

公开(公告)日：2016-01-07

申请号：US14856462

申请日：2015-09-16

Applicant: Idenix Pharmaceuticals LLC

Inventor： Benjamin Alexander MAYES ,  Adel M. MOUSSA ,  Alistair James STEWART ,  Gilles GOSSELIN ,  Christophe Claude PARSY ,  François-René ALEXANDRE ,  Jean-François GRIFFON ,  Dominique SURLERAUX ,  Cyril B. DOUSSON ,  Claire PIERRA ,  Houcine RAHALI

IPC: C07H19/20 ,  C07H19/10

CPC classification number: C07H19/20 ,  A61K31/403 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/55 ,  A61K45/06 ,  C07H19/10 ,  C07H19/16 ,  A61K2300/00

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.